



In your hemophilia B patients,

## Save on factor IX replacement therapy with AlphaNine SD

### Case Study—Patient: John S.\*

- 48-year-old, 80-kg (175 lbs) male with severe hemophilia B since early childhood, and not always managed
- John is having knee replacement surgery (target joint), secondary to chronic bleeds into the knee

\*Fictional patient. For illustration purposes only.

## Comparing AlphaNine SD with BeneFIX

### John's cost/volume comparison

#### AlphaNine SD<sup>1</sup>

- Dosage in surgery: 75 units/kg (every 12 hours x 10 days)
- Average adult weight: 80 kg
- Total doses: 20
- Total units: 120,000 (80 kg x 75 units/kg x 20 doses = 120,000 units of AlphaNine SD)

#### BeneFIX<sup>2</sup>

- Dosage in surgery: 97.5 units/kg (every 12 hours x 10 days)
- Average adult weight: 80 kg
- Total doses: 20
- Total units: 156,000 (80 kg x 97.5 units/kg x 20 doses = 156,000 units of BeneFIX)

#### Cost of therapy




- AlphaNine SD: 120,000 units x \$1.16<sup>†</sup> per unit\* = \$139,200
- BeneFIX: 156,000 units x \$1.63<sup>†</sup> per unit\* = \$254,280
- Potential cost savings when choosing AlphaNine SD over BeneFIX: \$115,080

### Calculations based on comparisons of recovery factors of AlphaNine SD (1.0) and BeneFIX (1.3)

<sup>†</sup>Average Sales Price (ASP) is calculated and reported quarterly by the Centers for Medicare and Medicaid Services (CMS) and is the payment amount used to pay for Medicare Part B covered drugs. The CMS ASP is average sales price +6% and includes an additional blood clotting factor furnishing fee of \$0.24 for Q3 2022. AlphaNine SD CMS ASP is \$1.16 as of Q322.

\*Hypothetical data calculated based on doses cited in clinical data.<sup>3</sup>

## For your patients with hemophilia B<sup>1</sup>

Potency	Diluent size	NDC numbers
 <b>500 IU FIX*</b> range	10 mL	68516-3607-2 or 68516-3610-2
 <b>1000 IU FIX</b> range	10 mL	68516-3608-2 or 68516-3611-2
 <b>1500 IU FIX</b> range	10 mL	668516-3609-2 or 68516-3612-2

- Every package of AlphaNine SD comes with a Mix2Vial®<sup>+</sup> device for easy reconstitution
- For convenient dosing, AlphaNine SD is available in a wide range of vial sizes
- The AlphaNine SD manufacturing process incorporates specific steps with the capacity to inactivate/remove a wide panel of viruses



## Indication

AlphaNine® SD (coagulation factor IX [human]) is indicated for the prevention and control of bleeding in patients with factor IX deficiency due to hemophilia B.

## Important Safety Information

AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of factor IX complex concentrates which contain high amounts of factor II, VII and X. AlphaNine SD contains low, nontherapeutic levels of factor II, VII and X.

Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.

Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to factor IX.

In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.

AlphaNine SD should not be administered at a rate exceeding 10mL/minute. Rapid administration may result in vasomotor reactions.

**Please see accompanying full Prescribing Information for AlphaNine SD.**

- References:** **1.** AlphaNine® SD (coagulation factor IX [human]) Prescribing Information. Grifols. **2.** BeneFIX Prescribing Information. Pfizer Inc. **3.** Quon DVK et al. *Haemophilia*. 2011;17(1):e196-e201.

\*FIX, factor IX.

<sup>+</sup>Mix2Vial® is a registered trademark of Medimop Medical Projects, Ltd., a subsidiary of West Pharmaceutical Services, Inc.

# GRIFOLS

© 2022 Grifols

All rights reserved

July 2022

US-A9-2200001